PHARMACAN CAPITAL CORP. (“MJN-V”) – Grants Stock Options

August 10, 2016

PHARMACAN CAPITAL CORP. (“MJN-V”) – Grants Stock Options

FOR IMMEDIATE RELEASE – NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

PharmaCan Capital Corp. (“PharmaCan” or the “Company”) announces it has granted options to subscribe to an aggregate of 975,000 common shares of the Company to Michael Gorenstein, the Company’s Chief Executive Officer, and to D HSU Ventures LLC, a Company consultant, the whole in accordance with the Company’s stock option plan. In addition, the Company has also granted options to subscribe to an aggregate of 250,000 common shares of the Company to the Company’s non-executive directors, the whole in accordance with the Company’s stock option plan. The options are exercisable at a price of $0.50 per common share, which was the closing price of the Company’s common shares on the TSX-V on August 4, 2016. The options shall expire at the earlier of 180 days of the death, disability or incapacity of the holder or five years after the date of issue. The grant of options is subject to the Company receiving all necessary and appropriate regulatory consents and approvals, if any, and to the Company’s stock option plan.

About PharmaCan

PharmaCan is a company in the business of investing in companies licensed to produce medical marihuana pursuant to Canada’s MMPR.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investor & Media Relations

Michael Krestell

PharmaCan Capital Corp.

Phone: (416) 603-7381 EXT #236

Email: michael@pharmacancapital.com

720 King Street West, Suite 320

Toronto, Ontario M5V 2T3

Info@TheCronosGroup.com
Careers@TheCronosGroup.com

(416) 504-0004